Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc daily Stock Chart
AMRN [NASD]
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.05 Insider Own0.90% Shs Outstand361.14M Perf Week-7.99%
Market Cap2.72B Forward P/E12.54 EPS next Y0.56 Insider Trans0.00% Shs Float144.35M Perf Month-6.77%
Income-18.80M PEG- EPS next Q-0.07 Inst Own45.30% Short Float26.41% Perf Quarter-59.89%
Sales511.50M P/S5.32 EPS this Y83.10% Inst Trans4.01% Short Ratio2.38 Perf Half Y-65.79%
Book/sh1.56 P/B4.50 EPS next Y711.10% ROA-2.40% Target Price- Perf Year-59.38%
Cash/sh1.40 P/C5.02 EPS next 5Y42.30% ROE-4.10% 52W Range3.95 - 26.12 Perf YTD-67.26%
Dividend- P/FCF- EPS past 5Y27.30% ROI-3.80% 52W High-73.12% Beta2.82
Dividend %- Quick Ratio2.30 Sales past 5Y51.30% Gross Margin77.80% 52W Low77.72% ATR0.51
Employees965 Current Ratio2.60 Sales Q/Q111.50% Oper. Margin-5.00% RSI (14)35.00 Volatility6.25% 7.05%
OptionableYes Debt/Eq0.07 EPS Q/Q23.40% Profit Margin-3.70% Rel Volume0.46 Prev Close7.02
ShortableYes LT Debt/Eq0.00 EarningsApr 30 BMO Payout- Avg Volume15.99M Price7.02
Recom2.20 SMA20-7.27% SMA50-11.00% SMA200-54.29% Volume0 Change0.00%
May-05-20Initiated Northland Capital Outperform $15
Mar-31-20Upgrade Oppenheimer Underperform → Perform
Mar-31-20Downgrade Jefferies Buy → Hold $30 → $4
Mar-31-20Downgrade Goldman Buy → Neutral
Mar-13-20Upgrade Goldman Neutral → Buy $28
Mar-02-20Initiated Cowen Outperform $23
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
Oct-15-19Initiated Goldman Neutral $17
Aug-14-19Initiated SVB Leerink Outperform $26
Jul-09-19Reiterated Jefferies Buy $30
Jun-17-19Initiated ROTH Capital Buy $31
Mar-22-19Initiated Stifel Buy $27
Nov-14-18Upgrade Citigroup Neutral → Buy
Nov-02-18Downgrade Citigroup Buy → Neutral
May-22-20 01:23PM  FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules Motley Fool
01:15PM  Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement Benzinga
09:07AM  Amarin Stock Is Falling. A Competitor Got Approval for a Generic Version of Its Heart Drug. Barrons.com
08:45AM  Amarin Down 10% in Pre-Market On Generic Approval SmarterAnalyst
08:22AM  1 Biotech Stock to Avoid at All Costs Motley Fool
07:10AM  The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray Benzinga
May-21-20 04:07PM  HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19 CNW Group
04:05PM  Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire
May-19-20 05:07AM  Is Amarin Stock a Buy? Motley Fool
May-15-20 06:14PM  Can Amarin (AMRN) Overcome Its Patent Headwinds? 5-Star Analyst Weighs In TipRanks
May-14-20 02:50PM  VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study GlobeNewswire
May-09-20 06:44AM  If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now Motley Fool
May-08-20 02:42PM  Edited Transcript of AMRN earnings conference call or presentation 30-Apr-20 11:30am GMT Thomson Reuters StreetEvents
May-06-20 11:26AM  Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil Zacks
May-05-20 12:17PM  Amarin (AMRN) Stock Could Stage a Rebound to $15, Says Analyst TipRanks
May-04-20 06:43PM  Amarin (AMRN): All Eyes on Vascepa Appeal Verdict TipRanks
05:26AM  Amarin's Shares March Higher, Can It Continue? Zacks
May-01-20 10:51AM  Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat Zacks
Apr-30-20 08:30PM  Amarin Corporation plc (AMRN) Q1 2020 Earnings Call Transcript Motley Fool -7.87%
09:08AM  Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops Zacks
07:19AM  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1 Benzinga
Apr-29-20 11:54AM  Is a Beat in Store for Amarin (AMRN) This Earnings Season? Zacks +5.63%
10:05AM  Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More Zacks
Apr-28-20 11:53AM  Edited Transcript of AMRN earnings conference call or presentation 13-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
07:00AM  Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020 GlobeNewswire
Apr-24-20 06:45PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm ACCESSWIRE +11.89%
Apr-21-20 04:25PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm ACCESSWIRE
Apr-16-20 08:33AM  Cramer Shares His Thoughts On Yext, Workday And More Benzinga
Apr-15-20 06:46AM  Here's Why Amarin (NASDAQ:AMRN) Can Manage Its Debt Despite Losing Money Simply Wall St.
Apr-14-20 07:59AM  The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership Benzinga
03:51AM  Amarin Reports Strong 1Q Vascepa Sales; Plans Patent Appeal For May SmarterAnalyst
Apr-13-20 06:17PM  Amarin Shares Recover Somewhat After US Patent Setback GuruFocus.com +5.62%
Apr-08-20 04:05PM  Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update GlobeNewswire +15.28%
Apr-06-20 11:44AM  Amarin (AMRN) Will Make Excellent Takeover Target, Says Analyst TipRanks
Apr-03-20 01:56PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire -8.43%
Apr-02-20 01:30PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm ACCESSWIRE
09:55AM  Is Amarin (AMRN) Stock a Solid Choice Right Now? Zacks
Apr-01-20 12:15PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $500,000 to Contact the Firm ACCESSWIRE +24.50%
11:01AM  Judges Record Looks Unpromising for Amarins Appeal; Analyst Remains Bullish TipRanks
Mar-31-20 06:19PM  INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire -70.54%
04:30PM  Amarin Stock Melts Down After Losing Patent Battle For Heart Drug Investor's Business Daily
12:00PM  Judicial Ruling Guts Amarin (AMRN) Stock; Whats Next? TipRanks
10:12AM  Amarin's Stock Plunges Following Unfavorable Patent Ruling Zacks
08:50AM  Amarin Investors Who Lost Money Should Contact Block & Leviton: The Firm Is Investigating Securities Fraud at the Company GlobeNewswire
08:49AM  Amarin's stock plummets on heavy volume after court rules in favor of makers of generic Vascepa MarketWatch
08:26AM  The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions Benzinga
07:20AM  Halliburton Soars, Amarin Slumps as Chinese Data Show Signs of Life Barrons.com
07:00AM  Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiologys Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
03:21AM  Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa Benzinga
Mar-30-20 06:37PM  Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report TheStreet.com
06:25PM  Amarin Comments on Ruling in VASCEPA® ANDA Litigation GlobeNewswire
11:45AM  Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes GlobeNewswire
Mar-25-20 09:29AM  Do Options Traders Know Something About Amarin (AMRN) Stock We Don't? Zacks
Mar-22-20 11:01PM  Hedge Funds Have Never Been This Bullish On Amarin Corporation (AMRN) Insider Monkey
Mar-20-20 08:10AM  Even If It Hurts Amarin Stock, Reducing the Vascepa Sales Push Is Smart InvestorPlace -7.72%
Mar-18-20 08:51AM  U.S. companies begin delaying clinical trials due to coronavirus outbreak Reuters
Mar-17-20 09:40AM  Goldman Sachs: 3 Stocks to Snap up on the Dip TipRanks
Mar-16-20 08:00AM  Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented at the American College of Cardiologys 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC), March 28 30 GlobeNewswire -18.25%
Mar-15-20 01:56PM  Amarin Takes Proactive Steps to Support Public Health Priorities GlobeNewswire
Mar-06-20 06:50AM  Amarin Stock Looks Like a Heart-Healthy Buy on the Dip InvestorPlace
Mar-04-20 10:49AM  The Charts of Amarin Tell Us That a Close Below $14 Is Key TheStreet.com
Mar-01-20 08:38AM  Introducing Amarin (NASDAQ:AMRN), The Stock That Soared 726% In The Last Five Years Simply Wall St.
Feb-28-20 02:48PM  Look Anywhere but Acasti Pharma Stock for Opportunity InvestorPlace
10:07AM  Confounding Decline Creates an Opportunity in Amarin Stock InvestorPlace
Feb-27-20 02:05PM  PreMarket Prep Stock Of The Day: Amarin Benzinga -9.83%
Feb-26-20 04:46PM  Edited Transcript of AMRN earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -7.03%
09:16AM  Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates Zacks
Feb-25-20 04:05PM  Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations GlobeNewswire
04:05PM  Amarin beats quarterly revenue estimates on strong Vascepa uptake Reuters
08:28AM  The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement Benzinga
Feb-21-20 05:50PM  Amarin (AMRN) Gains As Market Dips: What You Should Know Zacks
Feb-20-20 09:25AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
06:00AM  Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-19-20 04:15PM  Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020 GlobeNewswire
08:34AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks
Feb-18-20 08:48AM  Buy Amarin Stock Because It Has Fallen Far Enough, Analyst Says Barrons.com
Feb-14-20 01:44PM  Vascepa Growth Will Power Amarin Stock Way Higher in 2020 InvestorPlace
11:41AM  Risks Remain, but Amarin Stock Is a Buy at Todays Prices InvestorPlace
Feb-12-20 02:03PM  Will Positive Patent News Send Amarin Stock Higher? Analysts Fight It Out TipRanks
Feb-11-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-06-20 09:26PM  Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire
Feb-05-20 05:50PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-30-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
01:44PM  Amarin Stock's Outlook Not for the Faint of Heart TheStreet.com
Jan-28-20 01:48PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
06:30AM  HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl) CNW Group
Jan-23-20 09:31AM  A Tale of 3 Healthcare Stocks 2 to Buy, and 1 to Sell TipRanks
Jan-17-20 11:07AM  Does Acasti Stock Have a Future? InvestorPlace
06:30AM  Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace
Jan-16-20 05:37AM  Does Amarin Corporation plc's (NASDAQ:AMRN) CEO Pay Matter? Simply Wall St.
Jan-15-20 05:45PM  Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-14-20 09:46AM  AstraZeneca to End Phase III Study on Fish Oil Heart Drug Zacks
Jan-13-20 04:22PM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
02:31PM  Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint MarketWatch
11:07AM  Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short Barrons.com
09:40AM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
06:00AM  Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire
Jan-10-20 06:08PM  AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down Zacks -5.20%
01:02PM  Amarin Stock Bouncing Back After Revised Results and 2020 Guidance InvestorPlace
12:08PM  7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount InvestorPlace
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.